2014年12月12日讯/生物谷bioon /——treprostinil治疗重度慢性肺动脉高压患者的长期安全性和预后PA5463六世- 54 - 5 63 SP - PA5463盟Harutyunova Satenik盟——Benkamin尼古拉盟——Eichstaedt克里斯蒂娜AU -马拉,阿尔贝托·玛丽亚盟——Xanthouli Panagiota盟——Egenlauf本杰明盟——Grunig埃克哈德•Y1 - 2019/09/28 UR - //www.qdcxjkg.com/content/54/suppl_63/PA5463.abstract N2 -背景:前列环素(PCs)被用作肺动脉高压(PAH)的靶向治疗。目前缺乏关于肺动脉高压患者应用s.c.和/或经s.c. Corno静脉注射treprostinil (T)和可植入LENUS Pro泵的安全性和长期预后的数据。方法:37例PAH患者(20例女性，51±15 y.o.，平均肺动脉压62.3±14.4 mmHg，心脏指数2.4±0.7 L/min/m2, 6例WHO功能II级，26例III级，5例IV级)，使用三靶向PAH药物(ERA、PDE5抑制剂和treprostinil s.c.)，每3个月进行一次临床评估。采用Kaplan Mayer估计法进行生存率分析。结果:曲前列尼治疗3个月(p=0.021)、6个月(p=0.033)、12个月(p=0.042)后患者6分钟步行距离均有显著改善。治疗3个月和6个月后，三尖瓣环状平面收缩偏移、右房和右心室面积均有所改善(均p < 0.05)。平均6±0.9个月后，24例患者使用Lenus Pro泵系统静脉注射曲前列尼。两个泵在1.5±1个月后需要手术修复，另外4个泵在11±12个月后需要移除。 After a mean follow-up of 2.82±1.95 years, 12 patients died, three patients received lung transplantation. Transplant-free survival after 1 year was 85.7%, after 2 years 69.2% and after 3 years 65.3% (Figure).Conclusion: Subcutaneous T as add-on to double combination treatment significantly improved right heart size and function in this patient cohort. In most patients T could be continued i.v. by implanted Lenus Pro pump with a good overall-survival.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA5463.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -